By Carlo Martuscelli

MaxCyte Inc. (MXCT.LN) said Friday that its signed an agreement with Gilead Sciences Inc. (GILD) company Kite to help it develop CAR-T cancer therapies.

Life-sciences company MaxCyte said it will provide Kite with technology to help it engineer nonviral cells to develop CAR-T drug candidates. In return, MaxCyte is eligible to receive development and approval milestones and sales-based payments.

CAR-T therapy is an advanced treatment that uses patients' genetically-engineered immune cells to fight cancer.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

March 01, 2019 04:08 ET (09:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Maxcyte Charts.
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Maxcyte Charts.